Table 1 Baseline demographics and clinical characteristics of the participants.

From: Effects of Alzheimer’s genetic risk scores and CSF biomarkers in de novo Parkinson’s Disease

Variables

 

HCs (N = 195)

PD (N = 413)

P

Demographic

Age, years

60.84 (11.25)

61.65 (9.68)

0.386

Sex, female

69 (35.4%)

143 (34.6%)

0.854

Education, years

16.05 (2.90)

15.52 (2.97)

0.036

Duration, months

NA

6.65 (6.55)

 

Age at onset, years

NA

59.67 (9.94)

 

Follow-up duration, years

4.41 (1.35)

4.36 (1.34)

0.675

Genetic

APOE4 allele

0 = 145 (74.3%)

0 = 310 (75.1%)

0.98

 

1 = 45 (23.1%)

1 = 93 (22.5%)

 
 

2 = 5 (2.6%)

2 = 10 (2.4%)

 

GRS-AD

0.20 (0.69)

0.22 (0.66)

0.675

GRS-PD

−0.18 (0.67)

0.24 (0.73)

<0.001

CSF

Baseline Aβ42 (ng/mL)

1.02 (0.50)

0.90 (0.41)

0.007

 

Missing data = 8

Missing data = 12

 

Baseline t-tau (pg/mL)

191.58 (79.47)

169.38 (56.96)

0.001

 

Missing data = 9

Missing data = 19

 

Baseline p-tau (pg/mL)

17.52 (8.37)

14.85 (5.27)

<0.001

 

Missing data = 20

Missing data = 43

 

Baseline αSyn (ng/mL)

1.70 (0.75)

1.50 (0.67)

0.003

 

Missing data = 6

Missing data = 8

 

Baseline amyloid-positivity

59 (31.6%)

102 (25.4%)

0.540

 

Missing data = 8

Missing data = 12

 

Baseline p-tau/Aβ42 ratio

19.51 (17.70)

17.56 (9.48)

0.176

 

Missing data = 22

Missing data = 48

 

Longitudinal CSF measurement

166 (85.1)

354 (85.7)

0.946

Motor

UPDRS III score

1.21 (2.20)

20.79 (8.82)

<0.001

DAT scan

Mean caudate

2.98 (0.63)

2.00 (0.56)

<0.001

Mean putamen

2.14 (0.56)

0.83 (0.30)

<0.001

Mean striatum

2.56 (0.57)

1.41 (0.40)

<0.001

 

Missing data = 3

Missing data = 3

 

Cognitive

Visuospatial

13.13 (1.99)

12.77 (2.14)

0.042

Memory

9.30 (2.32)

8.36 (2.53)

<0.001

Semantic fluency

51.79 (11.23)

48.71 (11.67)

0.002

Frontal/executive

46.83 (10.53)

41.12 (9.71)

<0.001

 

Missing data = 0

Missing data = 1

 
  1. 42 42-residue amyloid-beta, αSyn Alpha-synuclein, AD Alzheimer’s disease, APOE4 Apolipoprotein E ε4 allele, CSF Cerebrospinal fluid, DAT Dopamine transporter, GRS Genetic risk score, HC Healthy controls, PD Parkinson’s disease, p-tau Phosphorylated tau, t-tau Total tau, UPDRS Unified Parkinson’s Disease Rating Scale.
  2. Data are expressed as a mean (standard deviation) or number (%). Results from t-tests or chi-square tests were used as appropriate.